Denali to sell FDA Priority Review Voucher for $195M cash

Filed June 18, 2026 · Period ending June 12, 2026 · ~1 min read

Key Changes

• high

  Denali agreed to sell its Rare Pediatric Disease Priority Review Voucher for $195 million in cash, awarded when the FDA approved its Hunter syndrome drug in March 2026.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →
• medium

  The sale remains subject to Hart-Scott-Rodino antitrust clearance; cash will be received at closing once regulatory waiting period expires.

  Item 1.01 — Entry into a Material Definitive Agreement verify on EDGAR →